Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Accumulated Depreciation & Amortization (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Accumulated Depreciation & Amortization readings, the most recent being $7.5 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 12.72% to $7.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 million, a 12.72% decrease, with the full-year FY2025 number at $7.5 million, down 12.72% from a year prior.
  • Accumulated Depreciation & Amortization hit $7.5 million in Q4 2025 for Amicus Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.5 million in Q4 2024 to a low of $1.3 million in Q1 2023.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $2.2 million (2023), compared with a mean of $3.7 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 75.87% in 2021 and later surged 342.53% in 2023.
  • Amicus Therapeutics' Accumulated Depreciation & Amortization stood at $6.2 million in 2021, then dropped by 13.96% to $5.3 million in 2022, then skyrocketed by 47.38% to $7.9 million in 2023, then grew by 8.56% to $8.5 million in 2024, then fell by 12.72% to $7.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $7.5 million (Q4 2025), $1.9 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.